Mobile website
Archive > Volume 23 Issue 6 > 2016,23(6):745-750. DOI:10.3872/j.issn.1007-385X.2016.06.002 Prev Next
Expert Forum
Toxic adverse reactions of CAR-T cellular immunotherapy for the patients with carcinoma and its clinical strategies
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Chimeric antigen receptor T cell (CAR-T) is an important approach of tumor immunotherapy, which has strong anti-tumor activity, but has clear clinical toxic adverse reactions. Through mechanisms of recognizing tissues with co-expressed target antigens and cross antigens, CAR-T could cause systemic injuries in whole body, namely tumor lysis syndrome (TLS) and cytokine release syndrome (CRS). Effective monitoring and real-time processing are key to prevention and treatment of the toxic adverse reactions. Combining with multiple clinical research results and experiences of CAR-T cellular immunotherapy for cancer the paper reviewed CAR-T cellular immunotherapy for cancer related toxic adverse reactions and its clinical strategies
Keywords:
Project Supported:
Project supported by the National Science and Technology Supporting Program (No.2015BAI12B12), the National Natural Science Foundation of China (No. 81171653， 31428005，31570877，31570908), and the Changzhou Science and Technology Plan (Applied Basic Research) Project (No.CJ20159021)
Clc Number:
